Robert Douglas Knight
Chief Medical OfficerDr. Robert Douglas Knight, also known as Bob, M.D, is Chief Medical Officer at NexImmune, Inc. since January 2021. He previously served as the Vice President of Clinical Development at Kite Pharmaceuticals, a Gilead company, from June 2020 to January 2021. Dr. Knight also led the cancer immunotherapy development program at Sorrento Therapeutics, Inc. as Senior Vice President and Head of Clinical Research from July 2017 to May 2020. Prior to that, Dr. Knight spent 16 years at Celgene Corporation as a Vice President in Clinical Research from June 2001 to June 2017. During his tenure at Celgene, he helped lead the development of the company’s IMiD and targeted therapy programs, including thalidomide, lenalidomide, and enasidenib. Dr. Knight is board certified in internal medicine, hematology, and oncology and has been an author on more than 90 peer-reviewed papers published in medical journals. Dr. Knight received his B.S. at United States Military Academy at West Point, New York and he received his M.D. from the State University of New York Downstate.
Positions
- Company NameNexImmune, Inc.Stock CodeNEXIPositionChief Medical OfficerColleagues
- JTJohn TrainerConsultant
- JSJonathan SchneckCo-Chairman of Scientific Advisory Board
- KHKaren HaslbeckHead of Human Resources
- DPDaniel P. BednarikSenior Vice President of Molecular Engineering & Protein Design
- CRChad RubinSenior Vice President of Corporate Affairs
- JSJeffrey S. WeberChief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB
- GTGerald T. NepomChair of Autoimmune & Infectious Disease Scientific Advisory Board
- MPMiguel-Angel PeralesMember of Scientific Advisory Board
- JVJuan VarelaMember of Scientific Advisory Board
